Given that anti-IgE therapy with omaluzimab is not approved for ABPA, and all monoclonal therapies for asthma are currently vastly too expensive for the majority of patients in low and middle income countries, antifungal therapy is an attractive option, if patients can be readily identified. Here, IGHE is linked to asthma.